Identification of a novel splice variant form of the influenza a virus m2 ion channel with an antigenically distinct ectodomain

Citation for published version:
Wise, HM, Hutchinson, EC, Jagger, BW, Stuart, AD, Kang, ZH, Robb, N, Schwartzman, LM, Kash, JC, Fodor, E, Firth, AE, Gog, JR, Taubenberger, JK & Digard, P 2012, 'Identification of a novel splice variant form of the influenza a virus m2 ion channel with an antigenically distinct ectodomain' PLoS Pathogens, vol 8, no. 11, e1002998. DOI: 10.1371/journal.ppat.1002998

Digital Object Identifier (DOI):
10.1371/journal.ppat.1002998

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
PLoS Pathogens

Publisher Rights Statement:
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Identification of a Novel Splice Variant Form of the Influenza A Virus M2 Ion Channel with an Antigenically Distinct Ectodomain

Helen M. Wise1,2, Edward C. Hutchinson1*, Brett W. Jagger1,3, Amanda D. Stuart1, Zi H. Kang1, Nicole Robb4, Louis M. Schwartzman3, John C. Kash3, Ervin Fodor4, Andrew E. Firth1, Julia R. Gog5, Jeffery K. Taubenberger3, Paul Digard1,2*.

1 Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom, 2 The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, United Kingdom, 3 Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 4 Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom, 5 DAMTP, Centre for Mathematical Sciences, University of Cambridge, Cambridge, United Kingdom

Abstract

Segment 7 of influenza A virus produces up to four mRNAs. Unspliced transcripts encode M1, spliced mRNA2 encodes the M2 ion channel, while protein products from spliced mRNAs 3 and 4 have not previously been identified. The M2 protein plays important roles in virus entry and assembly, and is a target for antiviral drugs and vaccination. Surprisingly, M2 is not essential for virus replication in a laboratory setting, although its loss attenuates the virus. To better understand how IAV might replicate without M2, we studied the reversion mechanism of an M2-null virus. Serial passage of a virus lacking the mRNA2 splice donor site identified a single nucleotide pseudoreverting mutation, which restored growth in cell culture and virulence in mice by upregulating mRNA4 synthesis rather than by reinstating mRNA2 production. We show that mRNA4 encodes a novel M2-related protein (designated M42) with an antigenically distinct ectodomain that can functionally replace M2 despite showing clear differences in intracellular localisation, being largely retained in the Golgi compartment. We also show that the expression of two distinct ion channel proteins is not unique to laboratory-adapted viruses but, most notably, was also a feature of the 1983 North American outbreak of H5N2 highly pathogenic avian influenza virus. In identifying a 14th influenza A polypeptide, our data reinforce the unexpectedly high coding capacity of the viral genome and have implications for virus evolution, as well as for understanding the role of M2 in the virus life cycle.

Citation: Wise HM, Hutchinson EC, Jagger BW, Stuart AD, Kang ZH, et al. (2012) Identification of a Novel Splice Variant Form of the Influenza A Virus M2 Ion Channel with an Antigenically Distinct Ectodomain. PLoS Pathog 8(11): e1002998. doi:10.1371/journal.ppat.1002998

Editor: Andrew Pekosz, Johns Hopkins University - Bloomberg School of Public Health, United States of America

Received November 18, 2011; Accepted September 13, 2012; Published November 1, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Introduction

Influenza A virus (IAV) is a genetically diverse pathogen of global significance, responsible for seasonal epidemics and sporadic pandemics in humans, as well as outbreaks in domestic animals. Its primary reservoir is wild birds, but it can infect a wide range of vertebrate species. For these reasons, there is the need to develop better therapeutics and vaccines [1]. Current vaccines target the surface glycoproteins haemagglutinin (HA) and neuraminidase (NA), but these proteins are subject to antigenic change, necessitating regular updating of the vaccine to ensure a good antigenic match to the circulating strains. Next generation influenza vaccines seek to induce broader or ‘universal’ protection against conserved epitopes; for example, the ‘stalk’ region of HA or the ectodomain of the matrix 2 ion channel protein (M2) [2,3].

The IAV genome consists of eight segments of negative sense, single stranded RNA (vRNA), each encapsidated into ribonucleoproteins (RNP)s by the viral RNA dependent RNA polymerase and multiple copies of the viral nucleoprotein (NP). Upon infection, incoming RNPs are imported into the nucleus, where the vRNA is transcribed to give positive sense mRNA, and also cRNA, which acts as a replication intermediate. The approximately 13 kb genome has so far been demonstrated to encode up to 13 proteins [4,5]. Segments 1, 4, 5 and 6 each encode a single protein: PB2, HA, NP and NA respectively. However, segments 2, 3, 7 and 8 have additional protein coding capacity. Segments 2 and 3, whose primary protein products are the polymerase proteins PB1 and PA respectively, additionally produce PB1-F2, PB1-N40 and PA-X proteins from single mRNA species by leaky ribosomal scanning and translation termination-reinitiation in the case of segment 2 and +1 ribosomal frameshifting for segment 3 [4–7].

In segments 7 and 8, protein coding capacity is expanded by differential mRNA splicing. For segment 8, a single spliced species
Influenza A virus is a pathogen capable of infecting a wide range of avian and mammalian hosts, causing seasonal epidemics and pandemics in humans. In recent years, the unexpected coding capacity of the virus has begun to be unravelled, with the identification of three more protein products (PB1-F2, PB1-N40 and PA-X) on top of the 10 viral proteins originally identified 30 years ago. Here, we identify a 14th primary translation product, made from segment 7. Previously established protein products from segment 7 include the matrix (M1) and ion channel (M2) proteins. M2, made from a spliced transcript, has multiple roles in the virus lifecycle including in entry and budding. In a laboratory setting, it is possible to generate M2 deficient viruses, but these are highly attenuated. However, upon serial passage a virus lacking the M2 splice donor site quickly recovered wild type growth properties, without reverting the original mutation. Instead we found a compensatory single nucleotide mutation had upregulated another segment 7 mRNA. This mRNA encoded a novel M2-like protein with a variant extracellular domain, which we called M42. M42 compensated for loss of M2 in tissue culture cells and animals, although it displayed some differences in subcellular localisation. Our study therefore identifies a further novel influenza protein and gives insights into the evolution of the virus.

Author Summary

Influenza A virus is a pathogen capable of infecting a wide range of avian and mammalian hosts, causing seasonal epidemics and pandemics in humans. In recent years, the unexpected coding capacity of the virus has begun to be unravelled, with the identification of three more protein products (PB1-F2, PB1-N40 and PA-X) on top of the 10 viral proteins originally identified 30 years ago. Here, we identify a 14th primary translation product, made from segment 7. Previously established protein products from segment 7 include the matrix (M1) and ion channel (M2) proteins. M2, made from a spliced transcript, has multiple roles in the virus lifecycle including in entry and budding. In a laboratory setting, it is possible to generate M2 deficient viruses, but these are highly attenuated. However, upon serial passage a virus lacking the M2 splice donor site quickly recovered wild type growth properties, without reverting the original mutation. Instead we found a compensatory single nucleotide mutation had upregulated another segment 7 mRNA. This mRNA encoded a novel M2-like protein with a variant extracellular domain, which we called M42. M42 compensated for loss of M2 in tissue culture cells and animals, although it displayed some differences in subcellular localisation. Our study therefore identifies a further novel influenza protein and gives insights into the evolution of the virus.
Also consistent with the western blot data, the unpassaged V7-T9 virus did not stain above background levels with the G74 antiserum, but the P6 isolate showed clear reactivity. However, the staining pattern was markedly different to that shown by WT virus, with prominent perinuclear staining and some staining of lateral membranes (Fig. 3B). Overall, these data suggested that the serially passaged M2 null virus had regained fitness by expressing a variant form of M2 that no longer reacted with the ectodomain-specific antibody.

Following serial passage, segment 7 of both the P6 WT and V7-T9 viruses was sequenced. No changes were detected in the WT virus compared to the reference sequence (GenBank accession...)

---

**Figure 1. Segment 7 transcript and ORF structure.**

(A). Diagrammatic summary of mRNA splice variants. The nucleotide coordinates of SD and SA sites are shown. Potential ORFs are colour coded (yellow, M1; blue, M2; red, unique sequence of M42) and total sizes (codons/aa) are given on the right. The arrowhead at top right indicates the binding site of the oligonucleotide used to detect the various mRNA species by radioactive primer extension reactions. (B) Nucleotide sequence (shown as cDNA) and predicted ORFs (colour coded as in (A)) of the 5′-end of PR8 mRNA4. Unused SD sequences and the splice junction (SJ) sequence are underlined. Nucleotides mutated to remove the M42 AUG codon (U115C) or abolish mRNA4 synthesis (G145A) are shown in red. (C) Alignment of the predicted N-terminal sequences of M2 and M42. The range of residues implicated in recognition of M2 by the 14C2 antibody are indicated in red [40–42,61]. The transmembrane domain of M2 is shaded in green.

doi:10.1371/journal.ppat.1002998.g001
EF467824). The P6 V7-T9 virus retained the original mutations that destroyed the mRNA2 SD site, indicating pseudoreversion to recover WT growth properties rather than true reversion. It also contained a single additional change, not seen in the original V7-T9 virus, of a U to A substitution at nucleotide 148 (U148A; mRNA sense, Fig. S1). This change is in the M2 intron and is silent in M1. However, the change would be predicted to improve the mRNA4 SD consensus (Fig. S1), from AG/GUA to AG/GUA [45]. As previously noted, mRNA4 is predicted to encode a 54 aa internally deleted version of M1 [12], from the first AUG on the transcript (Fig. 1B). Notably, the Kozak consensus [46] of AUG1 is not optimal, lacking a G at position 4 (Figs. 1B, S1) and in the context of segment 2, an intermediate strength initiation context. AUG1 is known to permit translation initiation at downstream codons by a leaky ribosomal scanning mechanism [4,6,7]. Inspection of the segment 7 sequence showed another AUG starting at position 114 in frame 2 (Fig. 1B). The predicted protein product from this AUG would have a variant ectodomain compared to M2, but would be identical from amino acid 10 onwards. The predicted size of the protein product would be 99 amino acids, compared to 97 for M2 (Fig. 1C).

Accordingly, we hypothesized that the U148A change induced pseudoreversion of the V7-T9 virus via upregulation of mRNA4, to produce a variant M2 protein (designated here “M42”) from AUG2 via leaky ribosomal scanning. To test this, we used reverse genetics to first ask whether the U148A change was sufficient to restore WT growth properties to the V7-T9 virus. Initially, a PR8 virus with only the U148A change grew to an average of 7 x 10^8 PFU/ml and formed normal-sized plaques (Fig. 4A). When the U7-T9, U148A or V7-T9+U148A mutations were made on the background of WT segment 7, as well as with the V7-T9, U148A or V7-T9+U148A mutations. On a WT background, a virus with only the U151C mutation grew normally and produced plaques indistinguishable from the WT virus (Fig. 4A). When the U151C mutation was combined with the U148A change, the resulting virus grew slightly less well than WT (an average relative titre of 0.44 [n = 4]) and displayed a small plaque phenotype. Addition of U151C to the V7-T9 mutant also had only a minor effect on growth relative to the parent virus. In contrast, its addition to the V7-T9+U148A background reversed the positive effect of the U148A mutation, resulting in a virus that grew poorly (to less than 10^4 PFU/ml) and produced small plaques. Similarly, the G145A mutation had no effect on virus growth as a single mutation or when combined with the U148A change. However, in 3 independent attempts, it was not possible to rescue a virus with V7-T9, U148A and G145A mutations, suggestive of a lethal phenotype.

These data indicated that pseudoreversion of the M2-null virus required mRNA4 and also AUG2. As an additional genetic test of the M42 hypothesis, we introduced two mutations that would be expected to block production of the predicted novel polypeptide: either by removing its AUG codon (U115C), or by destroying the mRNA4 SD site (G145A). Each of these mutations was made on the background of WT segment 7, as well as with the V7-T9, U148A or V7-T9+U148A mutations. On a WT background, a virus with only the U151C mutation grew normally and produced plaques indistinguishable from the WT virus (Fig. 4A). When the U115C mutation was combined with the U148A change, the resulting virus grew slightly less well than WT (an average relative titre of 0.44 [n = 4]) and displayed a small plaque phenotype. Addition of U115C to the V7-T9 mutant also had only a minor effect on growth relative to the parent virus. In contrast, its addition to the V7-T9+U148A background reversed the positive effect of the U148A mutation, resulting in a virus that grew poorly (to less than 10^4 PFU/ml) and produced small plaques. Similarly, the G145A mutation had no effect on virus growth as a single mutation or when combined with the U148A change. However, in 3 independent attempts, it was not possible to rescue a virus with V7-T9, U148A and G145A mutations, suggestive of a lethal phenotype.

To further test the M42 hypothesis, we introduced two mutations that would be expected to block production of the predicted novel polypeptide: either by removing its AUG codon (U115C), or by destroying the mRNA4 SD site (G145A). Each of these mutations was made on the background of WT segment 7, as well as with the V7-T9, U148A or V7-T9+U148A mutations. On a WT background, a virus with only the U151C mutation grew normally and produced plaques indistinguishable from the WT virus (Fig. 4A). When the U115C mutation was combined with the U148A change, the resulting virus grew slightly less well than WT (an average relative titre of 0.44 [n = 4]) and displayed a small plaque phenotype. Addition of U115C to the V7-T9 mutant also had only a minor effect on growth relative to the parent virus. In contrast, its addition to the V7-T9+U148A background reversed the positive effect of the U148A mutation, resulting in a virus that grew poorly (to less than 10^4 PFU/ml) and produced small plaques. Similarly, the G145A mutation had no effect on virus growth as a single mutation or when combined with the U148A change. However, in 3 independent attempts, it was not possible to rescue a virus with V7-T9, U148A and G145A mutations, suggestive of a lethal phenotype.

Identification of M42, a novel M2-related polypeptide

To provide biochemical evidence for the M42 hypothesis, we next examined segment 7 mRNA splicing by the panel of viruses in 293T cells. The V7-T9+U115C+U148A virus grew to insufficient...
titres to allow high multiplicity synchronous infections and the V7-T9+G145A+U148A virus could not be rescued, so the U115C+U148A and G145A+U148A viruses were used as proxies to analyse the effects of the U115C and G145A mutations on mRNA expression. Following infection, total RNA was extracted and reverse transcriptase-primer extension reactions were performed using a single primer capable of distinguishing segment 7 mRNAs 1–4 [17]. Separate primers specific for segment 7 vRNA and cellular 5S rRNA were also included as controls for virus infection and RNA recovery respectively. The levels of 5S rRNA were equivalent between samples (Fig. 4B), demonstrating equal loading. vRNA levels were also comparable between infected samples, suggesting that all infections had proceeded successfully. The levels of unspliced mRNA1 were also similar between the viruses. However, large differences in the levels of spliced mRNAs 2 and 4 were apparent. In cells infected with the WT virus, the unspliced transcript predominated, but abundant levels of mRNA2 (for M2) were also present (Fig. 4B, lane 1; quantification in Fig. 4C). In contrast, mRNAs 3 and 4 formed minor species that were only visible on long exposure (primary data not shown, but see Fig. 4C for quantification). As expected, mRNA2 was not detected in viruses containing the V7-T9 mutation (Fig. 4B, lanes 5 and 6). Importantly, and as predicted, the U148A mutation, either alone or on a V7-T9 background, strongly upregulated production of mRNA4 (compare lanes 1, 3 and 6). This effect was blocked when the mRNA4 SD was destroyed with a G145A change (lane 7). Interestingly, the changes in levels of mRNAs 2 and 4 were partly reciprocal. Loss of the mRNA2 SD site in the V7-T9 virus was associated with weak upregulation of mRNA4 (compare lanes 1 and 5), while improvement of the mRNA4 SD by the U148A change in an otherwise WT background led to around a three-fold drop in mRNA2 levels (compare lanes 1 and 3). Addition of the U115C change to the U148A virus caused a further decrease in mRNA2 levels, but left mRNA4 levels unaltered (compare lanes 3 and 4). Overall, these data supported the proposed mechanism of pseudoreversion involving increased production of mRNA4.

Next, we analysed segment 7 protein expression from the mutant viruses by western blotting for M1, and for M2 using I4C2

Figure 3. Immunofluorescent analysis of M2 expression. MDCK cells were infected with the indicated viruses at an MOI of 10, fixed at 8h p.i., permeabilised and stained with (A) anti M2 14C2 or (B) G74 (in green, as labeled) and (as counterstains) with anti-NP (red) and DAPI (blue) before imaging by confocal microscopy. Extended focus projections of a series of optical sections through the depth of the cells are shown, either as merged 3-colour images or (in grey scale), the green channel alone.
doi:10.1371/journal.ppat.1002998.g003
and G74 antisera. Lysates from the primary reverse genetics transfections in 293T cells were used, because V7-T9 + G145A or V7-T9 + G145A + U148A viruses could not be obtained. Virus polypeptides in these lysates will therefore come from several sources: from RNA Pol II transcription of the bidirectional plasmid, from viral transcription in cells where active RNPs have been reconstituted by transfection, and from spread of viable virus through the cell culture. To control for purely plasmid-mediated expression, lysates from a transfection where PB2 was omitted were probed. In this sample, levels of M1 and M2 were below the limit of detection, although they were readily visualised when all eight plasmids were transfected (Fig. 4D, compare lanes 1 and 2). This suggested that under these conditions, the major signal came from viral gene expression. When mutant and WT transfections were compared, M1 levels were broadly similar between samples, but there was more variation in M2 levels. As expected, 14C2 reactivity was only detected from viruses with an intact mRNA2 SD (lanes 7–12). G74 reactivity was also readily detectable in all samples from viruses able to make mRNA2. However, in the absence of mRNA2, it was only detectable in the V7-T9 + U148A transfected lysates (lane 10). Significantly, this was dependent on the presence of both elevated mRNA4 levels and segment 7 AUG2, as addition of either or the G145A or U115C mutations ablated its expression (compare lanes 10, 11 and 12).

Next, to prove the existence of the M42 polypeptide, we raised a specific antibody against a peptide corresponding to the predicted novel ectodomain of PR8 M42. To validate the serum, we tested it against transfected M42 and M2, both fused to GFP. M42-GFP, M2-GFP or GFP alone were transfected into 293T cells and the resulting cell lysates were probed with anti-M42 and anti-M2 14C2 or G74. Samples were also probed with anti-GFP and tubulin antisera, to confirm expression of the GFP polypeptides and equal sample loading respectively (Fig. 5A). The anti-M42 serum detected M42-GFP with a high degree of specificity over M2-GFP (compare lanes 1 and 2). Conversely, the 14C2 antibody

**Figure 4. Genetic and biochemical evidence for pseudoreversion through upregulation of mRNA4.** (A) Endpoint titres after multicycle replication in MDCK cells of viruses with the indicated mutations to segment 7. Values are plotted as the mean ± SEM of between 2 and 18 independent rescues. NR; not rescuable in 2 or more attempts. Viruses were also visually classified into normal (black bar) and small (white bar) plaque phenotypes. (B, C) Segment 7 mRNA accumulation. Total RNA isolated from cells infected with the indicated viruses at 6 h p.i. was analysed by RT-primer extension and urea-PAGE using primers specific for segment 7 mRNAs, vRNA or (as a loading control), cellular 5S rRNA. (C) The amounts of mRNAs 1–4 were quantified by phosphorimager and plotted as the mean ± SD of 3 experiments (D) Segment 7 polypeptide accumulation was monitored by western blot analysis of lysates from 293T cells transfected with reverse genetics plasmids for the indicated viruses at 72 h post transfection with the indicated antisera.

doi:10.1371/journal.ppat.1002998.g004
was specific for M2-GFP, while as expected, anti-G74 detected both M42 and M2-GFP. A preimmune bleed from the rabbits immunized with the M42 peptide did not react with either M42-or M2 GFP. To further probe the immunological cross-reactivity between M2 and M42, we tested a polyclonal antiserum raised against the entire M2 ectodomain, anti-M2e [48]. This reacted strongly with M2-GFP and only weakly with M42-GFP, confirming the novel antigenicity of the M42 ectodomain.

Having generated a specific M42 antibody, we investigated expression of the protein in cells infected with the panel of WT and mutant viruses. Western blot analysis of MDCK cell lysates from transfected with the indicated GFP polypeptides were analysed by SDS-PAGE and western blotting as labeled. (B) Detection of M42 from virus-infected cells. Lysates from cells infected with the indicated viruses at 10 h p.i. were analysed by SDS-PAGE and western blotting as labeled. The same membrane was probed with mouse anti-M2 14C2 and rabbit anti-M42 using different colour secondary antisera; individual grey scale and colour merged images are shown.

doi:10.1371/journal.ppat.1002998.g005

Figure 5. Direct detection of the M42 polypeptide. (A) Validation of anti-M42 serum. Lysates from cells transfected with the indicated GFP polypeptides were analysed by SDS-PAGE and western blotting as labeled. (B) Detection of M42 from virus-infected cells. Lysates from cells infected with the indicated viruses at 10 h p.i. were analysed by SDS-PAGE and western blotting as labeled. The same membrane was probed with mouse anti-M2 14C2 and rabbit anti-M42 using different colour secondary antisera; individual grey scale and colour merged images are shown.

doi:10.1371/journal.ppat.1002998.g005

was specific for M2-GFP, while as expected, anti-G74 detected both M42 and M2-GFP. A preimmune bleed from the rabbits immunized with the M42 peptide did not react with either M42-or M2 GFP. To further probe the immunological cross-reactivity between M2 and M42, we tested a polyclonal antiserum raised against the entire M2 ectodomain, anti-M2e [48]. This reacted strongly with M2-GFP and only weakly with M42-GFP, confirming the novel antigenicity of the M42 ectodomain.

Having generated a specific M42 antibody, we investigated expression of the protein in cells infected with the panel of WT and mutant viruses. Western blot analysis of MDCK cell lysates from transfected with the indicated GFP polypeptides were analysed by SDS-PAGE and western blotting as labeled. (B) Detection of M42 from virus-infected cells. Lysates from cells infected with the indicated viruses at 10 h p.i. were analysed by SDS-PAGE and western blotting as labeled. The same membrane was probed with mouse anti-M2 14C2 and rabbit anti-M42 using different colour secondary antisera; individual grey scale and colour merged images are shown.

doi:10.1371/journal.ppat.1002998.g005

was specific for M2-GFP, while as expected, anti-G74 detected both M42 and M2-GFP. A preimmune bleed from the rabbits immunized with the M42 peptide did not react with either M42-or M2 GFP. To further probe the immunological cross-reactivity between M2 and M42, we tested a polyclonal antiserum raised against the entire M2 ectodomain, anti-M2e [48]. This reacted strongly with M2-GFP and only weakly with M42-GFP, confirming the novel antigenicity of the M42 ectodomain.

Having generated a specific M42 antibody, we investigated expression of the protein in cells infected with the panel of WT and mutant viruses. Western blot analysis of MDCK cell lysates using anti-tubulin sera demonstrated equivalent loading of all samples while anti-M1 and anti-NP sera showed equal levels of infection except in mock infected cells (Fig. 5B). WT, U115C, G145A and G145A+U148A viruses expressed abundant quantities of a polypeptide that reacted with 14C2 and G74 anti-M2 sera (Fig. 5B, lanes 2–5 and 7). In contrast, the V7-T9 virus did not produce detectable levels of any M2-related polypeptide (lane 8). However, coinfommit, upregulation of mRNA4 on this background by the addition of the U148A mutation led to abundant synthesis of an anti-M42 reactive polypeptide (lane 9), confirming our hypothesis of a novel M2-related polypeptide. The U148A mutation also led to synthesis of readily detectable amounts of the M42 polypeptide when introduced into an otherwise WT background (lane 5). M42 reactivity was however lost on this background by mutation of AUG2 with the U115C change, or by mutation of the mRNA4 SD using G145A (lanes 6 and 7). Consistent with the mRNA abundance data, overall amounts of M2 were reduced by the U148A mutation, as judged by 14C2 and G74 staining (compare lanes 1 and 5). In addition, double staining the same blot with the mouse 14C2 antibody in red and the rabbit M2 antibody in green allowed the creation of a merged image (Fig. 5B, top panel) that illustrates the similar molecular weights of the M2 and M42 polypeptides, as well as their changing relative abundance in response to mutations to SD sites of mRNAs 2 and 4.

Immunofluorescent staining of P6 V7-T9-infected cells suggested that the two forms of M2 localized differently within infected cells (Fig. 3B). To test if this truly reflected a difference in behaviour of M42 compared to M2, we infected cells with the relevant recombinant viruses and examined M2 and M42 localization by immunofluorescence. In WT virus infected cells, M2 protein localized to the plasma membrane (visible as staining of lateral membranes in single optical slices through the midline of the cells) as well as internally, often in a perinuclear position (Fig. 6A). Double staining for M42 however, only produced background levels of fluorescent signal, similar to mock infected or V7-T9 infected cells. In contrast, cells infected with the V7-T9+U148A virus did not stain for M2 but stained strongly with anti-M42, with the M42 signal largely present in a perinuclear structure. Confirming that the two proteins did indeed localize differently in infected cells, when cells infected with the U148A virus (which expresses both proteins; Fig. 5B) were examined, the
two polypeptides displayed limited colocalisation in the perinuclear region, but were largely in separate regions of the cell (Fig. 6A). Double staining of cells infected with the V7-T9+U184A virus with anti-M42 sera and a variety of markers for the cellular exocytic pathway showed good co-localisation with GM130 (Fig. 6B and data not shown), indicating that M42 was largely resident in the cis-Golgi apparatus. To examine intracellular trafficking of M42 further, we created a plasmid encoding an M42-red fluorescent protein fusion (M42-mCherry) and examined the localization of the chimaeric protein in living cells, in comparison to a simultaneously transfected M2-GFP fusion. Both polypeptides co-localised in discrete cytoplasmic puncta and at the plasma membrane, but while the intensity of GFP and mCherry fluorescence was similar in the cytoplasmic dots, there was clearly less of the M42-mCherry protein on the plasma membrane than on the cytoplasmic membrane, although the intensity of GM130 was associated with distinct membrane-bounded structures. Examination of time lapse films showed that the cytoplasmic puncta showed the expected pattern of movement for intracellular vesicles (Videos S1, S2, S3). Overall therefore, we conclude that like M2, M42 enters the exocytic pathway, but its altered ectodomain affects intracellular trafficking of the protein, resulting in a lower proportion resident at the plasma membrane.

The marked difference in intracellular localization between M2 and M42 was surprising, given that the two proteins were apparently interchangeable with respect to virus replication in MDCK cells (Fig. 4A). We therefore tested the effect of modulating M42 expression on virus pathogenicity, using the murine infection model. When either BALB/c or C57BL/6 strain mice were infected with 100 PFU of WT PR8 virus, they lost weight rapidly (Figs. 7A, B), showing average peak weight losses of around 20% and substantial amounts of mortality (Fig. 7C). High titres of virus were also recoverable from the lungs of infected C57BL/6 mice at days 2 and 4 p.i., dropping somewhat at day 7 (Fig. 7D). In contrast, mice infected with the same titer of the M42-null V7-T9 virus showed minimal weight loss, few signs of illness or virus replication and no mortality. However, upregulation of mRNA4 synthesis via U148A on the V7-T9 background substantially increased virus replication and pathogenicity in terms of virus titres and weight loss, although the overall mortality was less than observed with WT virus. Conversely, increasing M42 expression by adding the U148A change on the background of a WT virus still able to express M2 had the opposite effect, decreasing the severity of weight loss and overall mortality, although lung titres were not affected. Removal of the M42 AUG codon with the U115C mutation had little effect in BALB/c mice but led to slightly delayed weight loss and decreased mortality in C57BL/6 mice. Overall therefore, altering the balance between M2 and M42 expression modulated virus pathogenicity, but a virus that only expressed M42 still caused significant disease.

Production of mRNA4 and M42 in other strains of influenza A

The work described above demonstrated that mRNA4 encodes a biologically significant polypeptide that can compensate for loss of M2 expression. The question therefore arose as to whether this might apply to other strains of IAV. The two requisites for M42 expression are production of mRNA4 and the possession of an AUG codon in the appropriate reading frame. mRNA4 was originally discovered in the WSN strain of virus but was not detected in the A/Udorn/72 (Udorn) strain, a difference proposed to result from a single nucleotide difference in the sequences immediately surrounding the splice site: AG/GCU in WSN versus AG/GUU in WSN versus AG/GCU in Udorn ([12]; see Fig. S1, which shows an alignment of the viruses used or discussed in this work, in addition to the consensus sequences of the major virus subtypes that have infected humans this century). To test this prediction, we compared mRNA4 synthesis in a panel of viruses with either GUA, GUU or GCU at the 5'-end of the mRNA4 intron. In agreement with the quality of match with the consensus SD sequence, mRNA4 was not detectable in the two viruses with a GCU sequence: human H3N2 Udorn and H1N1 A/USSR/77 (Fig. 8A, lanes 6 and 7), while it was most abundant in the PR8 U148A mutant (GUA; lane 2). The prediction was also partially supported when mRNA4 synthesis was examined in viruses with a GUU sequence immediately downstream of the SD site. Intermediate quantities

![Figure 6: Intracellular localization of M42](image-url)
of mRNA 4 were detected in RNA from WSN and Cambridge PR8 virus infected cells (lanes 4 and 5; note lower overall amounts of segment 7 mRNAs with the latter virus). Curiously however, mRNA4 was not seen from reverse genetics PR8 (compare lanes 3–5). This was despite segment 7 of this virus only differing from Cambridge PR8 and WSN at two nucleotide positions in the 5'–240 nucleotides, with neither change located near the mRNA4 SD sequence (Fig. S1 and data not shown). There were also notable differences in the amount of mRNA3 produced by the viruses, with WSN and Udorn making abundant quantities, A/USSR/77 rather less and all three PR8 viruses making very little (Fig. 8A). Thus mRNA4 production is predictable by examination of the SD consensus sequence, with GUA-GUU>GCU, although other unidentified sequence polymorphisms also play a role.

Figure 7. Pathogenicity of segment 7 mutant viruses in mice. Mice were inoculated with 100 PFU of the indicated viruses and (A, B) weight loss measured on a daily basis. Mice were euthanised if their body weights fell below 25% of the starting value. (A) BALB/c mice were used. Data plotted are the mean and SEM values from two independent experiments each using 5 mice/group. (B, D) C57BL/6 mice were used. Data plotted are the mean and SEM values from a single experiment with 5 mice/group. (C) Mean and SEM nadir weights from (A, B) are plotted. Numbers over the bars indicate the number of mice that survived/total group size. (D) Lung titres (mean and SEM) from mice sacrificed at the indicated days. Three mice on days 2 and 7 and four mice on day 4 postinfection were used. Dashed line indicates the lower limit of detection.

doi:10.1371/journal.ppat.1002998.g007
We therefore used this information to interrogate Genbank for IAV segment 7 sequences likely to express M42. As of October 2011, over three-quarters of the 20,236 viruses for which useful segment 7 sequence was available contain the M42 AUG (data not shown). An imperfect initiation context of the M1/M2 AUG codon (which is likely to be necessary to allow leaky ribosomal scanning) is a very highly conserved feature of IAV (only 3 of 17256 sequences covering the M1 AUG have an optimal G at position +4). However, the majority (~80%) of viruses are unlikely to produce substantial amounts of mRNA4, as they possess an unfavourable AG/GCU or otherwise non-canonical SD sequence. In 1998, Shih and colleagues identified 8 viruses likely to make appreciable amounts of mRNA4 [12]. Now, with an increased number of sequences available as well as a better understanding of the sequence elements necessary for expression of a third biologically active protein from segment 7, we identified around two dozen viruses likely to express M42 (Table 1), by virtue of containing an AUG codon at positions 114–116 and an mRNA4 SD sequence of AG/GU(U/A/G). These mostly fell into three partially overlapping groups: isolates from the early 20th Century (human isolates from the 1930s and two classic fowl plague highly pathogenic avian influenza (HPAI) viruses), viruses that had been adapted to replicate in mice (the WS family, two H3N2 isolates and PR8) and a set of HPAI isolates, mostly from the USA 1983 outbreak [49]. The latter H5N2 grouping seemed the most likely to express large amounts of M42 because of their AG/GUA mRNA4 SD sequence. In addition, the H5N2 outbreak spread widely, persisted for several years and resulted in the culling of 17,000,000 poultry [50], making it an important group of non-laboratory-derived viruses, even if represented on Genbank by relatively few sequenced isolates.

We therefore tested whether the AG/GUA mRNA4 SD consensus of the H5N2 viruses was biologically significant. For biosafety reasons, we used reverse genetics to create a PR8 reassortant (MPenn) with segment 7 from A/chicken/Pennsylvania/10210/1986 (Penn) as well as various mutant derivatives with alterations to the mRNA2 or 4 SD sequences or the M42 AUG codon (Fig. S1), and then analysed their segment 7 mRNA expression profiles. Analysis of viral RNA synthesis showed that, as predicted by the MPenn mRNA4 SD sequence, mRNA4 was the predominant species made from segment 7, accumulating to markedly higher levels than either the unspliced transcript or spliced mRNAs 2 and 3; a reversal of the ratios seen with the ‘prototype’ mRNA 4-expressing virus, WSN, where mRNA4 was the least abundant species (Fig. 8B, compare lanes 2 and 10). Mutations to the mRNA2 and mRNA4 SD sequences had the expected effects. Destruction of the mRNA2 SD sequence by a G52C change reduced mRNA2 accumulation to below detectable levels (lane 3). Removal of the mRNA4 splice site with the G145A change blocked detectable synthesis of mRNA4 with, as before, the side effect of upregulating mRNA2 and mRNA3 production (lane 5). Mutations that weakened the mRNA4 SD consensus (A148G/U or C) dramatically reduced mRNA4 accumulation whilst simultaneously improving synthesis of mRNAs 2 and 3 (lanes 6–9). Also as expected, these changes were specific to segment mRNA, as the levels of segment 7 vRNA and segment 5 mRNA and cRNA were much more consistent between viruses (Fig. 8B).

Next the impact of these changes on virus growth were assessed. The WT MPenn reassortant virus grew well, reaching titres of around 10^7 PFU/ml (Fig. 8C). Abolition of mRNA2 expression (G52C) had no effect on virus replication; in contrast to the attenuation seen when M2 synthesis was blocked in other virus strains [15,36–39]. Similarly, mutations predicted to block M42 expression by destroying its AUG codon (U115C) or mRNA4 production (G145A) had no effect on virus growth. A similar lack of effect on virus titres were seen from the mutations that attenuated mRNA4 production: A148G, A148U and A148C. However, double mutations targeting both M2 and M42 production were deleterious to virus growth. Viruses lacking the M42 AUG codon or mRNA4 SD sequence could not be rescued (in 3 attempts) in combination with the G52C mRNA 2 SD
knockout (Fig. 8C). Moderate downregulation of mRNA4 production by an A148G change in the absence of mRNA2 synthesis led to a virus that grew to high titres but with a small plaque phenotype, while a more severe downregulation of mRNA4 synthesis with an A148U change resulted in an additional phenotype of very poor growth. Overall, these data indicate that the A/chicken/Pennsylvania/10210/1986 segment 7 expresses two functionally redundant versions of the viral ion channel, either one of which is sufficient to support replication in cultured cells. Thus M42 expression is not peculiar to laboratory adapted viruses but is likely to have been a feature of a major group of HPAI viruses that circulated for four years in North America.

**Discussion**

Here, we demonstrate expression of a 14th IAV polypeptide; a variant form of the M2 protein with an alternative ectodomain, encoded by a distinct segment 7 mRNA. This novel protein, M42, can functionally replace M2 and support efficient replication in tissue culture cells and pathogenicity in an animal host, despite showing clear phenotypic differences with respect to its intracellular localization. We have not directly tested M42 for proton conductance but the PR8 MUd virus engineered to express M42 rather than M2 retained amantadine sensitivity (data not shown), providing indirect evidence that the protein retains this function, as expected from its identical transmembrane domain sequence to M2. The ability of M42 to support efficient virus replication despite its inefficient transport to the plasma membrane is interesting in light of current theories regarding the role of M2 in membrane scission [32].

Like the three other IAV “accessory” genes that were discovered long after the virus genome was sequenced (PB1-F2, PB1-N40 and PA-X; [4–6]), M42 is clearly non-essential for virus replication, as long as sufficient M2 is expressed. Unlike the additional proteins expressed from the P protein genes, M42 expression is likely to be restricted to a minority of IAV strains under normal conditions, as a result of the suboptimal SD sequence of mRNA4. Examination of the consensus sequences for the major subtypes of IAV that have infected humans in the last century showed that (in consensus, with occasional exceptions) all possess[ed] a weak mRNA4 SD sequence (GCU at the intron boundary) of the type found in Udorn (Fig. S1). However, all these viruses except the current 2009 swine-origin pandemic virus also contain the M42 AUG codon as well as an imperfect Kozak

### Table 1. Viruses known or likely to express M42.

| Accession | SD   | Virus name                     | Year | Notes |
|-----------|------|--------------------------------|------|-------|
| L37797    | AG/GU| A/chicken/Weybridge (H7N7)      | 1927 | (a)   |
| L25814    | AG/GU| A/NWS/1933 (H1N1)              | 1933 | (b)   |
| M19374    | AG/GU| A/WSN/1933 (H1N1)              | 1933 | (b)   |
| EF467824  | AG/GU| A/Puerto Rico/8/34 (H1N1)      | 1934 | (c)   |
| M55474    | AG/GU| A/chicken/Rostock/1934 (H7N1)  | 1934 | (a)   |
| CY019956  | AG/GU| A/Alaska/1935 (H1N1)           | 1935 |       |
| X08090    | AG/GU| A/Port Chalmers/1/1973-mouse adapted (H3N2) | 1973 | (b)   |
| CY114430  | AG/GU| A/Bangkok/1/1979 (H3N2)        | 1979 |       |
| CY065977  | AG/GU| A/Philippines/2-MA/1982 (H3N2) | 1982 | (b)   |
| CY043729  | AG/GU| A/Siena/3/1991 (H3N2)          | 1991 |       |
| FJ784879  | AG/GU| A/chicken/Hunan/1793/2007 (H5N1) | 2007 | (a)   |
| GU052788  | AG/GU| A/chicken/Pennsylvania/21525/1983 (H5N2) | 1983 | (a)   |
| FJ610128  | AG/GU| A/chicken/MA/11801/1986 (H5N2) | 1986 | (a)   |
| CY015074  | AG/GU| A/chicken/Pennsylvania/1/1983 (H5N2) | 1983 | (a)   |
| GU052756  | AG/GU| A/turkey/Virginia/6962/1983 (H5N2) | 1983 | (a)   |
| GU052780  | AG/GU| A/chicken/Florida/27716-2/1986 (H5N2) | 1986 | (a)   |
| FJ610122  | AG/GU| A/chicken/NJ/12508/1986 (H5N2) | 1986 | (a)   |
| EU980474  | AG/GU| A/chicken/OH/22911-10/1986 (H5N2) | 1986 | (a)   |
| GU052748  | AG/GU| A/chicken/Pennsylvania/10210/1986 (H5N2) | 1986 | (a)   |
| FJS57092  | AG/GU| A/guinea fowl/OH/22911-20/1986 (H5N2) | 1986 | (a)   |
| EU743053  | AG/GU| A/chicken/NY/12004-3/1987 (H5N2) | 1987 | (a)   |
| EU743234  | AG/GU| A/goose/OH/22911-2/1986 (H5N2) | 1986 | (a)   |
| GU052772  | AG/GUG| A/chicken/Pennsylvania/1370/1983 (H5N2) | 1983 | (a)   |
| EU743059  | AG/GUG| A/chicken/FL/22780-2/1988 (H5N2) | 1988 | (a)   |
| GU052740  | AG/GUG| A/chicken/Pennsylvania/4104/1983 (H5N2) | 1983 | (a)   |

20,245 sequences available on the NCBI database were analysed on Oct 10th, 2011, with a repeat search for new sequences of the form AG/GU on July 2nd 2012. The table excludes duplicate sequences, PR8 vaccine reassortants and over 50 cases where supposedly unique sequences showed phylogenetically implausible levels of similarity to PR8 or WSN, suggestive of mistakes in data curation or laboratory contamination of virus stocks.

[a]Highly pathogenic avian influenza virus, by the molecular definition of possessing a polybasic HA cleavage site.

[c]Change from AG/GCU SD sequence seen after virus adapted to replicate in mice.

[b]Mouse adapted virus but original virus sequence not available.

doi:10.1371/journal.ppat.1002998.t001
consensus around the M1/M2 AUG codon (Fig. S1), suggesting the potential for M42 expression should mRNA4 expression be present. This perhaps argues that there are environments in which it is advantageous for IAV to shift the balance of segment 7 splicing away from the normal mRNAs/M2 route to increased mRNAs/M42. In this respect it is noteworthy that increased mRNAs synthesis has been selected for on at least three, probably four, occasions on different virus backgrounds during adaptation to growth in mice (Table 1). Also, given the Golgi-biased localisation of M42, it is tempting to draw a link between the requirement for pH-modulation of the Golgi during intracellular transport of HA molecules with polybasic cleavage sites [25,51] and the overrepresentation of HPAI viruses in the list of those likely to express M42. We also speculate that the altered antigenicity of the M42 ectodomain might provide the virus with a route to escape selection pressure imposed by a vaccine directed against the M2e sequence, given that in many viruses, a single nucleotide change would be predicted to alter the balance of splicing towards M42.

The viruses in which we can be reasonably confident of M42 expression represent a very small minority (~0.2%) of the available sequences. However, there are two further considerations that may render M42 expression more widespread in IAV than our conservative prediction in Table 1. Firstly, we do not yet fully understand what controls segment 7 splicing. A sizeable number of viruses (around 15%; mostly from avian hosts) have an mRNA4 sequence of AG/GCA. An A at position 2 is U but it +2.

Furthermore, the differences in relative splicing seen between PR8 and WSN viruses make it clear that sequence elements outside of the core consensus splice sites affect their use; these sequences are identical in the two viruses but their splicing patterns are very different. Analysis of a 7+1 PR8/WSN reassortant indicates that the difference is intrinsic to segment 7 (HW, PD, unpublished data) but we have not yet identified the sequence determinants. Secondly, there are many precedents for cell-type dependence of alternative splicing in cellular mRNAs [52] so it may be that in some host species and/or cell types, M42 expression is present in a wider array of IAV strains. Further experiments are required to test these hypotheses.

Materials and Methods

Ethics statement

Animal experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals under the auspices of an NIH Animal Care and Use Committee-approved animal study protocol. The protocol was approved by the NIAID Animal Care and Use Committee (Permit Number LID-6E). All efforts were made to minimize suffering.

Cells, viruses, plasmids and antisera

Madin-Darby Canine Kidney, 293T human embryonic kidney and A499 human lung adenocarcinoma cells were cultured according to standard procedures [53]. A reverse genetics clone of influenza PR8 and its M2-null derivative, V7-T9 have been previously described [37,47]. A clone of A/chicken/Pennsylvania/10210/1986 (GU052748) with the UTRs derived from A/chicken/Pennsylvania/1/1983 (CY015074; where a complete segment sequence was available) was synthesized by GenScript and cloned into pDUAL reverse genetics vector [47]. Further mutants were made using the 8 bidirectional promoter plasmid system described in [47], following oligonucleotide-directed mutagenesis to introduce the desired changes, as indicated in Fig. S1. Primer sequences are available upon request. Non-recombinant Cambridge lineage PR8 virus, A/ USSR/77 and A/WSN/33 viruses were obtained from the University of Cambridge Division of Virology’s collection of viruses. A/Udorn/72 was a gift from Professor Comans [54]. M2 and M42-GFP tagged expression constructs were produced by cloning the coding sequences of the respective proteins into the KpnI/AgeI sites of pEGFP-N1 (Clontech). An M42-mCherry fusion was made by substituting the EGFP open reading frame with mCherry. Purchased monoclonal antisera were against β-tubulin (clone YLI/2; AbD-Serotec), GM130 (Clone 610822; BD Transduction Laboratory), GFP (clone JL8, Clontech) and anti-influenza M2 (Clone 14C2, Abcam). Further anti-M2 reagents of a goat polyclonal (G74) raised against the whole protein and a mouse polyclonal raised against the M2 ectodomain (M2e) were the generous gifts of Drs. Alan Hay and Xavier Saelens, respectively. Rabbit polyclonal anti-M1 (A2917) and anti-NP (A2915) have been previously described [55,56]. Affinity purified anti-M42 specific serum was purchased from GenScript. Rabbits were immunized with a peptide corresponding to the N-terminal 16 amino acids of the protein, MSLOGRTPILRPRIRNE (where unique sequences compared to M2 are underlined).

Virus rescue, growth and titration

Recombinant viruses were rescued by 8 plasmid transfection into 293T cells followed by amplification in MDCK cells as previously described [37]. In some cases, stocks were further amplified by growth in day 10–12 embryonated eggs, also as described [37]. Tissue culture cells were infected by allowing virus to adsorb for 30–60 min in serum free medium. For synchronous analyses of viral RNA and protein synthesis, infections were carried out at an MOI of 3–10. For analyses of virus growth, infections were initiated at low multiplicity and cells overlaid with serum free medium supplemented with ۳۰۰ μg/ml trypsin (Worthington Biochemicals) and 0.14% bovine serum albumin. Serial passages were performed by infecting ۳×۱۰۵ MDCK cells at an MOI of 0.1. At 48 h p.i., the medium was clarified and ۱۰ μl (of 5 ml) used to infect fresh MDCK cells. This procedure was repeated a further five times.

Plaque assays were carried out in MDCK cells using an Avicel overlay followed by staining with toluidine blue [37,57]. Plaque areas were measured from scanned images using an oval selection marquee in the program Image J [58] and calibrated with respect to the area of a 6-well dish. HA assays were performed using 1% chicken red blood cells in 96 well plates according to standard procedures [37].

Mouse infection

Infection of C57BL/6J or BALB/c mice (strains 664 and 1026, JAX Mice and Services) was carried out under animal BSL3 conditions at the National Institutes of Health. Groups of five 9–10 week old female mice were infected intranasally with ۱۰۰ PFU of virus in ۵۰ μl DMEM under oxygenated isoflurane anaesthesia. Mice were individually identified and weighed daily; mice losing ۲۵% or more of their initial body weight were euthanised. Three mice on days 2 and 7 and four mice on day 4 postinfection were euthanised and lungs collected for weight-normalized homogenization and MDCK plaque titration.

RNA and protein analyses

Total cellular RNA was extracted using Trizol (Sigma) and individual RNA species detected using radiolabelled reverse
transcriptase primer extension followed by urca-PAGE, and autoradiography as previously described [17,59]. The primer GAAGGCCCTCTCTTTCAGTCC, which targeted nucleotides 885–904 in mRNA sense, was used to detect segment 7 mRNA. Quantitation was performed using Fujiﬁlm imaging plates and a Fujiﬁlm FLA-5000 ﬂuorescent image analyser. Data was analysed using AIDA software. (Raytest). SDS-PAGE followed by western blotting was performed according to standard procedures. Blots were developed using infrared ﬂuorescent secondary antibodies and imaged using a LiCor Biosciences Odyssey platform. Cells were stained for immunofluorescence after formaldehyde ﬁxation using primary followed by Alexa-thior conjugated secondary antibodies (Invitrogen) as previously described [60] and imaged on Zeiss LSM510, Leica SPE or TCS-NT confocal microscopes. Live cell imaging was performed in a temperature-controlled hood and CO2-independent medium as previously described [53].

Supporting Information

Figure S1 Alignment of IAV segment 7 splice site sequences from strains either used or discussed in this study. Individual cDNA sequences are shown for PR8 (Reverse sequences from strains either used or discussed in this underlined. Positions mutated in PR8 or Penn segment 7 in this in August 2011. AUG codons are highlighted in bold and by multiple alignment of publicly available sequences on GenBank viruses as well as human-derived H5N1 post 1997) were generated (324335) and Penn (GU052748) viruses. Partial consensus

References

1. Salomon R, Webster RG (2009) The inﬂuenza virus enigma. Cell 136: 402–410.
2. Du L, Zhou Y, Jiang S (2010) Research and development of universal inﬂuenza vaccines. Microbes Infect 12: 280–286.
3. Fiers W, De Fryste M, El Bakkeri K, Schepens B, Roose K, et al. (2009) M2-based universal inﬂuenza A vaccine. Vaccine 27: 6280–6283.
4. Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, et al. (2009) A complicated message: Identiﬁcation of a novel PIBI-protein translated from inﬂuenza A virus segment 2 mRNA. J Virol 83: 8921–8931.
5. Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, et al. (2011) An overlapping protein-coding region in inﬂuenza A virus segment 3 modulates the host response. Science 337: 199–204.
6. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, et al. (2001) A novel inﬂuenza A virus mitochondrial protein that induces cell death. Nat Med 7: 1306–1312.
7. Wise HM, Barbezange C, Jagger BW, Dalton RM, Gog JR, et al. (2011) Overlapping signals for translational regulation and packaging of inﬂuenza A virus segment 2. Nucleic Acids Res 39: 7775–7790.
8. Ingli SC, Gehring MJ, Brown CM (1980) Relationship between the messenger RNAs transcribed from two overlapping genes of inﬂuenza virus. Nucleic Acids Res 8: 3573–3590.
9. Lamb RA, Lai CJ (1980) Sequence of interrupted and uninterrupted mRNAs and cloned DNA coding for the two overlapping nonstructural proteins of inﬂuenza virus. Cell 21: 475–485.
10. Ingli SC, Brown CM (1981) Spliced and unspliced RNAs encoded by virus RNA segment 7 of inﬂuenza virus. Nucleic Acids Res 9: 2727–2740.
11. Lamb RA, Lai CJ, Choppin PW (1981) Sequences of mRNAs derived from genome RNA segment 7 of inﬂuenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc Natl Acad Sci U S A 78: 4170–4174.
12. Shih SR, Suen PC, Chen YS, Chang SC (1998) A novel spliced transcript of inﬂuenza A/WSN/33 virus. Virus Genes 17: 179–183.
13. Lamb RA, Choppin PW (1981) Identiﬁcation of a second protein (M2) encoded by RNA segment 7 of inﬂuenza virus. Virology 112: 729–737.
14. Shih SR, Nemerof ME, Krug RM (1995) The choice of alternative 5′ splice sites in inﬂuenza virus M1 mRNA is regulated by the viral polymerase complex. Proc Natl Acad Sci U S A 92: 6324–6329.
15. Chiang C, Chen GW, Shih SR (2008) Mutations at alternative 5′ splice sites of M1 mRNA negatively affect inﬂuenza A virus viability and growth rate. J Virol 82: 10873–10886.
16. Jackson D, Lamb RA (2008) The inﬂuenza A virus spliced messenger RNA M mRNA is not required for viral replication in tissue culture. J Gen Virol 89: 3957–3961.
17. Robb NC, Fedor E (2011) The accumulation of inﬂuenza A virus segment 7 spliced mRNAs is regulated by the NS1 protein. J Gen Virol In press.
18. Holsinger LJ, Lamb RA (1991) Inﬂuenza virus M2 integral membrane protein is a homodimer stabilized by formation of disulﬁde bonds. Virology 185: 32–43.
19. Sugrue RJ, Hay AJ (1991) Structural characteristics of the M2 protein of inﬂuenza A viruses: evidence that it forms a tetrameric channel. Virology 180: 617–624.
20. Schnell JR, Chou JJ (2006) Structure and mechanism of the M2 protein channel of inﬂuenza virus. Nature 441: 391–398.
21. Piekol RM, Chou JJ (2011) Inﬂuenza M2 proton channels. Biochim Biophys Acta 1808: 522–529.
22. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH (1985) The molecular basis of the speciﬁc anti-inﬂuenza action of amantadine. Embo J 4: 3021–3024.
23. Pinto LH, Holsinger LJ, Lamb RA (1992) Inﬂuenza virus M2 protein has ion channel activity. Cell 69: 517–528.
24. Bukurinskaya AG, Vorkunova NK, Pushkarzskaya NL (1982) Uncouating of a rimantadine-resistant variant of inﬂuenza virus in the presence of rimantadine. J Gen Virol 60: 61–66.
25. Sugrue RJ, Bahadur G, Zambon MC, Hall-Smith M, Douglas AR, et al. (1990) Speciﬁc structural alteration of the inﬂuenza haemagglutinin by amantadine. EMBO J 9: 3469–3476.
26. Chen BJ, Leser GP, Jackson D, Lamb RA (2008) The inﬂuenza virus M2 protein cytoplasmic tail interacts with the M1 protein and inﬂuences virus assembly at the site of virus budding. J Virol 82: 10659–10670.
27. Greenham ML, Stewart SM, Laline EN, Pekosz A (2010) Tyrosines in the inﬂuenza A virus M2 protein cytoplasmic tail are critical for production of infectious virus particles. J Virol 84: 8765–8776.
28. Iwatsuki-Horimoto K, Horimoto T, Nozta T, Kato M, Mardja J, et al. (2006) The cytoplasmic tail of the inﬂuenza A virus M2 protein plays a role in viral assembly. J Virol 80: 5233–5240.
29. McGown MF, Pekosz A (2005) The inﬂuenza A virus M2 cytoplasmic tail is required for infectious virus production and efﬁcient genome packaging. J Virol 79: 3565–3560.
30. McGown MF, Pekosz A (2006) Distinct domains of the inﬂuenza A virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 80: 8178–8189.

Acknowledgments

We thank Dr. Stacey Estathiou for help with animal experiments and Professors X. Saelens and A. Hay for gifts of antisera.

Author Contributions

Conceived and designed the experiments: HMW ECH BWJ ADS JCK PD. Performed the experiments: HMW ECH BWJ ADS ZHK LR LMS JCK. Analyzed the data: HMW ECH BWJ ADS ZHK LR LMS JCK EF AEF JRG JKT PD. Contributed reagents/materials/analysis tools: NR EF AEF JRG JKT PD. Wrote the paper: HMW ECH BWJ PD.
31. Rosman JS, Jing X, Leser GP, Balanik V, Pinto LH, et al. (2010) Influenza virus M2 channel protein is necessary for filamentous virion formation. J Virol 84: 5078–5088.

32. Rosman JS, Jing X, Leser GP, Lamb RA (2010) Influenza virus M2 protein mediates ESCRT-independent membrane scission. Cell 142: 902–913.

33. Parks GD, Hall JD, Lamb RA (1989) Transposition of domains between the M2 and HN viral membrane proteins results in polyproteins which can adopt more than one membrane orientation. J Cell Biol 109: 2023–2032.

34. Parks GD, Lamb RA (1991) Topology of eukaryotic type II membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain. Cell 64: 777–787.

35. Park EK, Castrucci MR, Pomer A, Kawakoa Y (1996) The M2 ectodomain is important for its incorporation into influenza A viruses. J Virol 70: 2449–2455.

36. Cheung TK, Guan Y, Ng SS, Chen H, Wong CH, et al. (2005) Generation of recombinant influenza A virus without M2 ion-channel protein by introduction of a point mutation at the 3′ end of the viral intron. J Gen Virol 86: 1447–1454.

37. Hutchinson EC, Curran MD, Read EK, Gog JR, Digard P (2008) Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus. J Virol 82: 11069–11079.

38. Watanabe T, Watanabe S, Ito H, Kida H, Kawakoa Y (2001) Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J Virol 75: 5656–5662.

39. Takeda M, Pekoz A, Shuck K, Pinto LH, Lamb RA (2002) Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 76: 1391–1399.

40. Wang R, Song A, Levin J, Dennis D, Zhang NJ, et al. (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 ion-channel protein. Antiviral Res 80: 168–177.

41. Zhirnov OP, Konakova TE, Wolff T, Klenk HD (2002) NS1 protein of influenza A virus matrix protein 2 is not immunoprotective. J Gen Virol 93: 301–306.

42. Da Foote M, Ysenbaert T, Roose K, Schotsaert M, Roels S, et al. (2011) Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective. J Gen Virol 92: 1379–1386.

43. Suarez DL, Sene DA (2000) Sequence analysis of related low-pathogenic and highly pathogenic H5N2 avian influenza isolates from United States live bird markets and poultry farms from 1983 to 1989. Avian Dis 44: 356–364.

44. Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y (2001) Influenza A virus down-regulates apoptosis. J Virol 76: 1617–1625.

45. Kozak M (1986) Point mutations define a sequence flanking the AUG initiation codon that modulates translation by eukaryotic ribosomes. Cell 44: 283–292.